Trial Profile
AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 25%≤LVEF≤35%
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms ADMIRE-ICD
- Sponsors GE Healthcare
- 23 Jan 2019 Status changed from suspended to discontinued.
- 28 Mar 2018 This trial has been Discontinued in Hungary .
- 26 Mar 2018 Status changed from recruiting to suspended due to suspended - Recruitment rate